Condition: SLE - Systemic Lupus Erythematosus · Sponsor: Miltenyi Biomedicine GmbH
This is a phase l/ll open-label, multicentre, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE systemic lupus erythematosus. In the phase I part, a maximum of n=12 patients will be treated in a maximum of 3 dose levels. In the phase IIa part, a maximum of n=17 will be treated (n=10 patients in a 1st stage + n=7 patients in a 2nd stage). This includes the patients from the phase I part treated on the recommended dose level.
This description comes directly from the study's public registry record.
Clinical Trial Manager · +4922048306820 · clinicaltrials.gov@miltenyi.com
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Erlangen, Medizinische Klinik 3 | Erlangen, Germany | Not Yet Recruiting |
| Otto-von-Guericke-Universität Magdeburg | Magdeburg, Germany | Recruiting |
| Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06189157